Berlin, Germany – A new experimental obesity drug developed jointly by Roche and Zealand Pharma is showing promising results in a mid-stage clinical trial, with patients experiencing weight loss of up to 10.7% over 42 weeks. The findings, released Thursday, offer a potential new avenue in the fight against obesity, a growing global health crisis. While the results are encouraging, experts caution that the drug, known as petrelintide, demonstrated a lower efficacy than some other recently tested weight loss medications.
The phase 2 trial involved 493 patients and compared the effects of petrelintide to a placebo. Participants receiving the drug experienced a significantly greater reduction in body weight compared to those in the placebo group, who saw a decline of just 1.7%. The data suggests petrelintide could become a valuable tool in managing obesity, a condition linked to a range of serious health problems, including heart disease, type 2 diabetes, and certain cancers. Roche gained access to petrelintide through a licensing agreement with Zealand Pharma, valued at up to $5.3 billion, signaling a significant investment in the drug’s potential.
How Petrelintide Works: Mimicking a Key Hormone
Petrelintide functions as an amylin analog, meaning it mimics the effects of the naturally occurring hormone amylin. Amylin is co-secreted with insulin and plays a role in regulating appetite and slowing gastric emptying. By activating amylin receptors in the brain and digestive system, petrelintide aims to reduce food intake and promote a feeling of fullness. This mechanism differs from the popular GLP-1 receptor agonists like Wegovy and Zepbound, currently dominating the weight loss market. The unique approach of petrelintide could potentially lead to fewer side effects and may offer benefits in preserving muscle mass, according to researchers.
Comparing Petrelintide to Eli Lilly’s Eloralintide
The results of the petrelintide trial are being closely compared to those of eloralintide, another amylin-mimicking drug candidate developed by Eli Lilly. In a mid-stage study, eloralintide demonstrated a more substantial weight loss of up to 20.1% after 48 weeks. Analysts previously estimated that a weight loss in the range of 12% to 13%, adjusted for placebo, would be necessary for petrelintide to be competitive with eloralintide. However, direct comparisons are complicated by differences in trial demographics, particularly the proportion of female participants.
Morningstar analyst Karen Andersen highlighted the importance of gender in treatment response. “The weight loss efficacy is clearly below what we saw for eloralintide — but it’s too really hard to compare these trials, as females respond so much better to treatment,” Andersen stated. The Zealand Pharma trial included 53% female participants, while the Lilly trial had a higher proportion of women at 78%. Data from the Zealand trial indicated that female participants experienced approximately six percentage points more weight loss than male participants on a placebo-adjusted basis.
Placebo Tolerability and Potential Advantages
A key feature of petrelintide highlighted by Zealand Pharma is its “placebo-like tolerability.” This suggests the drug is well-tolerated by patients, with minimal side effects. This is a significant advantage, as some existing weight loss medications can cause unpleasant gastrointestinal issues. Reuters reported that Roche is hoping to capitalize on this aspect as it enters the increasingly competitive obesity drug market, currently led by Novo Nordisk and Eli Lilly.
The Growing Obesity Drug Market
The market for obesity medications is experiencing rapid growth, driven by the increasing prevalence of obesity worldwide and a growing awareness of its health consequences. Novo Nordisk’s Wegovy and Zepbound have demonstrated significant weight loss results and have become highly sought-after treatments. However, supply chain issues and high demand have led to shortages of these medications. The entry of new players like Roche and Zealand Pharma with petrelintide could help alleviate these challenges and provide more options for patients.
What’s Next for Petrelintide?
Roche and Zealand Pharma are now preparing to move petrelintide into late-stage clinical trials, which will involve a larger and more diverse patient population. These trials will be crucial in confirming the drug’s efficacy and safety profile. If the results are positive, the companies plan to seek regulatory approval from health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The timeline for potential market availability remains uncertain, but analysts predict it could be several years before petrelintide reaches patients.
David Kendall, Zealand’s chief medical officer, emphasized the ongoing research and development efforts. On a call with analysts, he discussed the observed differences in weight loss between male and female participants and the potential for optimizing treatment strategies based on gender. Further investigation into these factors could help maximize the drug’s effectiveness for all patients.
Key Takeaways
- Petrelintide, a new obesity drug from Roche and Zealand Pharma, demonstrated up to 10.7% weight loss in a mid-stage trial.
- The drug mimics the amylin hormone, offering a different mechanism of action compared to existing GLP-1 agonists.
- Petrelintide showed “placebo-like tolerability,” suggesting minimal side effects.
- While effective, petrelintide’s weight loss results were lower than those seen with Eli Lilly’s eloralintide.
- The drug is moving into late-stage trials, with potential market availability several years away.
The development of petrelintide represents another step forward in the ongoing effort to address the global obesity epidemic. While challenges remain, the prospect of new and effective treatments offers hope for millions of individuals struggling with this complex health condition. The next phase of clinical trials will be critical in determining the drug’s ultimate potential and its place in the evolving landscape of obesity management.
Investors and healthcare professionals will be closely watching the progress of petrelintide as it moves through the regulatory process. Further updates on the drug’s development are expected in the coming months. The companies have not yet announced a specific timeline for the start of late-stage trials, but they have indicated their commitment to bringing this potential new treatment to market as quickly as possible.
Do you have thoughts on the latest developments in obesity treatment? Share your comments below, and please share this article with your network.